Biogen's Diranersen Drug Shows Promise in Slowing Alzheimer's Progression

Initial clinical trial results for Biogen's experimental Alzheimer's drug, diranersen, have shown promising results. When administered to multiple sclerosis patients, the drug slowed cognitive decline by 30%. This suggests potential for early-stage Alzheimer's prevention. The experimental medication reduced amyloid plaque formation, allowing brain cells to function more efficiently. Biogen plans to advance diranersen to broader clinical trials. The development could mark a significant breakthrough in Alzheimer's treatment.